This approach works by inhibiting inflammation and angiogenesis in the PMN through ANG-2 blockade and by preventing the recruitment of tumor-promoting CCR2+ Tie2-TAMs.328 Chemokines and CSF1 are known to play crucial roles in the recruitment of monocytes to tumors and the PMN, as well as in shaping their function within the TME.329,330 However, targeting chemokines alone or in combination has not yielded positive clinical outcomes, leading to the discontinuation of this strategy. Here, CCR2 is linked to neoplasm.